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Abstract 
The abundant adrenal C19 steroid 11β-hydroxyandrostenedione (11OHA4) has been 
written off as a dead-end product of adrenal steroidogenesis. However, recent 
evidence has demonstrated that 11OHA4 is the precursor to the potent androgenic 
11-oxygenated steroids, 11-ketotestosterone and 11-ketodihydrotestosterone, that 
bind and activate the human androgen receptor similarly to testosterone and DHT. 
The significance of this discovery becomes apparent when considering androgen 
dependent diseases such as castration resistant prostate cancer and diseases 
associated with androgen excess, e.g. congenital adrenal hyperplasia and polycystic 
ovary syndrome. In this paper we describe the production and metabolism of 11-
oxygenated steroids. We subsequently discuss their androgenic activity and highlight 
the putative role of these androgens in disease states. 
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1. Introduction 
The production of the C19 steroids androstenedione (A4), dehydroepiandrosterone 
(DHEA) and DHEA sulphate (DHEAS) by the zona reticularis of the adrenal cortex is 
well documented. Although it has long been established that the C19 steroid 11β-
hydroxyandrostenedione (11OHA4) is also an abundant product of human 
steroidogenesis, this metabolite has been written off as a by-product of 
steroidogenesis and is seldom included in the adrenal steroidogenic pathway. 
Recent studies however, revealed that 11OHA4 is not a dead-end product of 
steroidogenesis, but that it serves as the precursor to androgenic 11-oxygenated 
steroids, both in the adrenal itself and in the periphery. In this review we evaluate the 
production of these 11-oxygenated steroids, their androgenic activity and discuss the 
potential contribution of these steroids to disease states. 
2. Biosynthesis of C19 steroids in the human adrenal   
The biosynthesis of C19 adrenal steroids occurs primarily in the zona reticularis of 
the adrenal cortex (Fig. 1). The enzymes involved in these biosynthetic pathways 
were recently reviewed in detail by Turcu et al. (Turcu et al., 2014). C19 steroids, like 
all steroid hormones, are derived from the 27-carbon molecule cholesterol. Steroid 
biosynthesis commences with the transfer of cholesterol from the outer to inner 
mitochondrial membrane by steroidogenic acute regulatory protein (StAR). 
Thereafter, cholesterol undergoes the cleavage of the side chain to produce 
pregnenolone (PREG), a C21 steroid, via the action of the cytochrome P450 side-
chain cleavage enzyme (CYP11A1). PREG is further metabolised by the 17α-
hydroxylase activity of CYP17A1 to form 17α-hydroxypregnenolone (17OH-PREG). 
Thereafter, the 17,20-lyase activity of CYP17A1, augmented by cytochrome b5, 
cleaves the 17-20 carbon bond yielding the C19 steroid DHEA  (Auchus, 2004; Miller 
and Auchus, 2011; Rainey et al., 2002; Turcu et al., 2014). This Δ5 pathway is the 
preferred route to C19 steroid production in humans as the 17,20 lyase activity of 
human CYP17A1 does not efficiently convert 17α-hydroxyprogesterone (17OH-
PROG) to A4 (Auchus et al., 1998).  
In humans, a dramatic increase in adrenal C19 steroid production is observed during 
adrenarche, with clinical signs physiologically observed between the ages of 6 and 
10  (Auchus and Rainey, 2004; Rainey et al., 2002; Rege and Rainey, 2012). It is 
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worth noting that premature adrenarche can represent a forerunner of metabolic 
disease (Idkowiak et al., 2011).  
Interestingly, the process of adrenarche occurs much more gradually then previously 
assumed (Remer et al., 2015) and encompasses the formation of a distinct zona 
reticularis, in which the enzyme expression is altered from that of the zona 
fasciculata, resulting in the production of C19 steroids (Turcu et al., 2014). During 
adrenarche, the expression of cytochrome b5, which augments the 17,20-lyase 
activity of CYP17A1, is upregulated in the zona reticularis, while the expression of 
3β-hydroxysteroid dehydrogenase type 2 (3βHSD2) is downregulated. This 
combination of expression promotes the flux though the Δ5 pathway leading to DHEA 
production without the conversion of the Δ5 PREG and 17OH-PREG to their 
respective Δ4 metabolites by 3βHSD2. While some of the resulting DHEA is released 
directly into circulation, much of this steroid is first sulfonated by the activity of 
SULT2A1, resulting in the release of DHEAS into circulation  (Auchus and Rainey, 
2004; Mueller et al., 2015; Rainey and Nakamura, 2008; Rege and Rainey, 2012). 
DHEA is also converted to A4 by 3βHSD2. It has been proposed that A4 production 
occurs in a layer of cells between the zona fasiculata and the zona reticularis which 
expresses CYP17A1, cytochrome b5 and 3βHSD2  (Nakamura et al., 2011; Nguyen 
et al., 2016; Rainey and Nakamura, 2008).  Despite low expression of 3βHSD2 in the 
zona reticularis, A4 is produced in this zone and may be facilitated by cytochrome b5, 
which has also been shown to upregulate the activity of 3βHSD (Goosen et al., 2013, 
2011; K. Storbeck et al., 2013).  
The expression of aldo-keto reductase 1C3 (AKR1C3), also known as 17β-
hydroxysteroid dehydrogenase type 5 (17βHSD5), in the zona reticularis also results 
in the conversion of DHEA and A4 to androstenediol and testosterone, respectively. 
Androstenediol, in turn, is converted to testosterone by 3βHSD2. The adrenal gland 
is a major source of circulating androgens in women, with the levels of circulating 
androgens decreased by >90% in female patients with adrenal insufficiency (W Arlt 
et al., 1999). Conversely the adrenal only makes a minor contribution to circulating 
testosterone levels in men. However, at a tissue-specific level both men and women 
generate active androgens from DHEA (Arlt et al., 1998; Wiebke Arlt et al., 1999). 
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In addition to the C19 steroids described above, the human adrenal produces 
significant quantities of the 11-oxygenated C19 steroid 11OHA4 (Axelrod et al., 
1973; Dorfman, 1954; Holownia et al., 1992; Jeanloz et al., 1953; Rege et al., 2013; 
Touchstone et al., 1955), which is formed by the CYP11B1-catalysed 11β-
hydroxylation of A4 (Fig 1) (Schloms et al., 2012; Swart et al., 2013; Turcu et al., 
2016). Interestingly, the adrenal produces more 11OHA4 than A4 under both normal 
(Table 1) and adrenocorticotropin (ACTH)-stimulated conditions (Rege et al., 2013). 
Low quantities of the 11-oxygenated steroids 11-ketoandrostenedione (11KA4), 11β-
hydroxytestosterone (11OHT) and 11-ketotestosterone (11KT) are also produced by 
the human adrenal (Table 1). 11KA4 is produced by the conversion of 11OHA4 by 
low levels of 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) expressed in the 
adrenal (Rege et al., 2013; K.-H. Storbeck et al., 2013). 11KA4 is in turn a substrate 
for AKR1C3, yielding 11KT (K.-H. Storbeck et al., 2013). Although it has been 
proposed that 11OHA4 is converted to 11OHT by AKR1C3 (Rege et al., 2013; Turcu 
et al., 2014), we have shown that neither AKR1C3 nor 17β-hydroxysteroid 
dehydrogenase type 3 (17βHSD3) catalyses this reaction (K.-H. Storbeck et al. 
2013; unpublished data). Instead, 11OHT can be produced by the CYP11B1 
catalysed 11β-hydroxylation of testosterone (Schloms et al., 2012). 11OHT is, in 
turn, a substrate for 11βHSD2, yielding 11KT.  
Turcu et al recently showed that in patients with steroid 21-hydroxylase deficiency 
(21OHD) the levels of 11KT correlate well with those of 11OHT, suggesting that 
11OHT is the primary precursor to 11KT. Furthermore, this study found a correlation 
between T and 11KT in woman, again suggesting that the 11β-hydroxylation of T to 
11OHT provides the precursor for 11KT production in the adrenal. Moreover, the 
circulating pool of 11OHT and 11KT was found to be similar in men and women, 
thereby confirming that the adrenal is likely the primary site of 11OHT and 11KT 
biosynthesis and that gonadal T is not an important precursor (Turcu et al., 2016). 
Even though the adrenal expresses low levels of 11βHSD2, differences in the 
concentration of the individual 11-oxygenated steroids in the adrenal vein and 
inferior vena cava suggest that while 11OHA4 and 11OHT are products of the 
adrenal, 11KA4 and 11KT may be formed in peripheral target tissues of androgen 
action rather than in the adrenal glands (Rege et al., 2013; Turcu et al., 2016).  
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3. Androgenicity of the 11-oxygenated steroids  
Studies in 1950s and 1960s revealed that both 11OHA4 and 11KA4 (often referred 
to as adrenosterone in older literature), which were known to be products of the 
human adrenal, had negligible androgenic activity (Byrnes and Shipley, 1955; 
Dorfman and Dorfman, 1963; Rosemberg and Dorfman, 1958). Unlike 11OHA4, A4 
was recognised as an important precursor to active androgens leading to the 
suggestion that the 11β-hydroxylation of A4 served as a mechanism to inactivate this 
androgen precursor (Bélanger et al., 1993; Goldzieher et al., 1978; Labrie et al., 
1988). A general loss of interest in the function of 11-oxygenated C19 steroids in 
mammals followed and 11OHA4 and its metabolites have, in most cases, been left 
out of the steroidogenic scheme, despite 11OHA4 being an abundant product of 
adrenal steroidogenesis (Table 1) (Rege et al., 2013). In contrast to the case in 
mammals, the role of 11-oxygenated steroids in teleost fish was firmly established. In 
these fish, which produce varying levels of 11OHA4, 11KA4, 11OHT and 11KT 
(Jiang et al., 1998, 1996; Liu et al., 2000), 11KT functions as the primary androgen 
(Borg, 1994).  
Interestingly, despite the seeming lack of interest in the role of 11-oxogenated C19 
steroids, 11KA4 is widely promoted as a prohormone in dietary supplements (usually 
referred to as 11-oxoandrostenedione or 11-OXO), capable of reducing body fat and 
increasing muscle mass (Brooker et al., 2009; de la Torre et al., 2015). To our 
knowledge, evidence for the effect of 11KA4 on muscle mass is taken from studies 
conducted in fish (Lone and Matty, 1982). It has also been proposed that 11KA4 
functions as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1), 
which catalyses the conversion of cortisone to cortisol. A reduction in cortisol, a 
catabolic hormone, is thought to be beneficial for increasing muscle mass. 11KA4 
supplements are therefore sometimes promoted as ‘selective cortisol modulators’ 
(Brooker et al., 2009). We have shown that 11KA4 is in fact a substrate for 11βHSD1 
(Swart et al., 2013), and any inhibition is therefore likely due to competition between 
the substrates. Due to the anabolic nature of 11KA4, presumably by conversion to 
11KT, and its ability to modulate cortisol levels, 11KA4 is considered a performance 
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enhancing drug and a number of doping control methods have been developed in 
order to detect its usage (Brooker et al., 2009; de la Torre et al., 2015). 
Despite the prominent androgenic role played by 11KT in fish and the claimed 
androgenic effects of supplements containing 11KA4, very few studies have 
considered the potential androgenic activity of the 11-oxygenated steroids in 
mammalian systems. In 2008, Yazawa et al. showed that CYP11B1 expression 
could be induced in both Leydig cells and ovarian theca cells from immature mice by 
treatment with human chorionic gonadotropinin, leading to the production of 11OHT 
and 11KT (Yazawa et al., 2008). More importantly, this study was the first, to our 
knowledge, to investigate the androgenic activity of 11OHT and 11KT, which were 
up until that point only considered fish androgens, via a mammalian androgen 
receptor (AR). They found that 11KT demonstrated similar activity to testosterone, 
while 11OHT demonstrated poor androgenic activity, similar to that of A4. After 
confirming that 11OHA4, 11KA4, 11OHT and 11KT are products of the human 
adrenal, Rege et al. used MDA-kb2 cells, containing a human AR and an androgen 
receptor-driven luciferase reporter to show that 11OHT and 11KT both have similar, 
albeit slightly lower, androgenic activity to that of testosterone via the human AR 
(Table 2). They confirmed that 11OHA4 has no androgenic activity, and that 11KA4 
is only slightly androgenic (Rege et al., 2013). In the same year, our group showed 
that 11KT is a partial AR agonist at 1 nM, comparable to T. We found that the 
11OHA4 metabolites, 11K-5α-dione, 11OHT and 11OHDHT also demonstrated 
partial agonist activity at 1 nM, albeit less than that of 11KT. Significantly, we found 
that 11-ketodihydrotestosterone  (11KDHT), the 5α-reduced product of 11KT, acted 
as a full AR agonist at 1 nM, comparable to DHT (Table 2) (K.-H. Storbeck et al., 
2013). While developing a cell based androgen screening model Campana et al. 
recently confirmed that 11KT is a full AR agonist whereas 11OHT is only a partial AR 
agonist.  In their test system 11KA4 elicited only a low, but detectable response, 
while no response was observed for 11OHA4 (Campana et al., 2016).    
We subsequently conducted a comparative study of the androgenic activity of 
testosterone, DHT, 11KT and 11KDHT. First, we showed that 11KT and 11KDHT 
bind to the human AR with affinities similar to that of T and DHT. Next, we used a 
selective androgen response element-driven luciferase reporter to assess the 
potencies and efficacies of the four androgens via the human AR. We found that 
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both the potencies and efficacies of 11KT and 11KDHT are comparable to that of T 
and DHT, respectively (Table 2). To our knowledge, this was the first study to show 
that 11KDHT is equipotent to DHT, which is considered the most potent natural 
androgen in mammals. Finally, we confirmed that 11KT and 11KDHT, like T and 
DHT, were able to induce AR-regulated gene expression and cell growth in two 
androgen dependent prostate cancer cell lines (Pretorius et al., 2016). 
It is therefore apparent that there is a growing body of evidence supporting not only 
the production of 11-oxygenated steroids by the human adrenal, but also the 
androgenic activity of these steroids and their metabolites (Pretorius et al., 2016; 
Rege et al., 2013; K.-H. Storbeck et al., 2013). While the role of these steroids in 
normal human physiology will take time to elucidate, there is increased interest in the 
role that these steroids may play in disease conditions which are either dependent 
on adrenal C19 steroids or associated with androgen excess, as will be discussed 
below.  
4. Castration resistant prostate cancer 
Prostate cancer is an androgen-dependent and -driven disease. As such, the first 
line of treatment for advanced prostate cancer is androgen deprivation therapy 
(ADT) which is accomplished by either surgical (Orchiectomy) or chemical castration 
using luteinizing-hormone-releasing-hormone (LHRH) agonists or antagonists 
(Sharifi, N., Gulley, J.L., Dahut, 2005). This approach significantly lowers the levels 
of circulating T (Heidenreich et al., 2014; Zlotta and Debruyne, 2005) which is the 
precursor to the most potent natural androgen, DHT. While ADT is initially effective, 
the cancer often later re-emerges in the form of castration resistant prostate cancer 
(CRPC), which is eventually fatal. Subsequent treatment, targeting androgen 
synthesis and action, has revealed that in most cases CRPC remains androgen 
dependent. These include the clinical results obtained with the CYP17A1 inhibitor, 
abiraterone (Attard et al., 2009a, 2009b; Fizazi et al., 2012) and the AR antagonist 
enzalutamide (Scher et al., 2012). Various mechanisms for the resurgence of  
androgen action have been proposed and include AR gene amplification, AR splice 
variants and AR mutations within CRPC cells (Holzbeierlein et al., 2004; Knudsen 
and Penning, 2010; Yuan and Balk, 2009; Zlotta and Debruyne, 2005). Furthermore, 
studies have shown that while ADT results in a 90 to 95% reduction in serum T 
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levels, intraprostatic DHT levels are only decreased by approximately 50% (Luu-The 
et al., 2008), thereby implicating steroids other than T as precursors to DHT. It has 
since been confirmed that a variety of adrenal steroids can serve as precursors to 
DHT in tissue such as the prostate, containing the necessary enzymatic machinery. 
After ADT, the transcriptional profile of key steroidogenic enzymes in the prostate is 
altered. The expression of 3βHSD1, steroid 5α-reductase type 1 (SRD5A1) and 
AKR1C3 is increased, while that of SRD5A2 is downregulated (Shaw et al., 2016; 
Stanbrough, 2006; Titus et al., 2005). 
The adrenal C19 steroids, DHEA, DHEAS and  A4 are substrates for the so called 
"alternate 5α-dione pathway", which bypasses T to produce DHT via 5α-
androstanedione (5α-dione) (Fig. 2) (Auchus, 2004; Chang and Sharifi, 2012; Chang 
et al., 2011; Luu-The et al., 2008; Miller and Auchus, 2011; Sharifi and Auchus, 
2014, 2012; Sharifi, 2012). In this pathway, SRD5A1 preferentially metabolises A4 to 
5α-dione rather than T to DHT (Chang et al., 2011; Thigpen et al., 1993). 5α-dione is 
subsequently converted to DHT by the action of AKR1C3 (Chang et al., 2011; 
Knudsen and Penning, 2010).  
While there is no doubt that the abovementioned pathways play a significant role in 
CRPC, the intratumoral androgen pool may not be limited to classical androgens 
such as testosterone and DHT. We have recently shown that prostate cancer cell 
lines are able to metabolise the abundant adrenal steroid 11OHA4, yielding the 
potent 11-oxygenated androgens 11KT and 11KDHT (Fig. 2) (Storbeck et al 2013). 
11OHA4 is metabolised by the same enzymes responsible for the conversion of the 
adrenal steroid A4 to DHT, namely AKR1C3 and SRD5A1. The 11OHA4 pathway 
however, also requires 11βHSD2 which is expressed in prostate cancer cells (Dovio 
et al., 2009; Page et al., 1994). The preferred route for 11OHA4 metabolism appears 
to be the conversion of 11OHA4 to 11KA4 by 11βHSD2, followed by the conversion 
of 11KA4 to 11KT by AKR1C3. 11KT in turn, is reduced by SRD5A1 to produce 
11KDHT. Interestingly, this suggests that the alternate 5α-dione and 11OHA4 
pathways may be complementary, with the 5α-dione pathway bypassing T, while the 
11OHA4 pathway favours the production of 11KT. The low levels of 11OHT, which is 
a partial AR agonist, may also contribute to the intratumoral androgen pool. 11OHT 
can be converted to 11OHA4 by 17β-hydroxysteroid dehydrogenase type 2 
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(17βHSD2) and then  to 11KT by the 11OHA4 pathway, or it can be converted 
directly to 11KT by the action of 11βHSD2 (Storbeck et al 2013). 
The products of the 11OHA4 pathway, 11KT and 11KDHT, have recently been 
confirmed to be potent AR agonists comparable to T and DHT, respectively  (Table 
2) (Pretorius et al., 2016). Furthermore, we have shown that these steroids are able 
to induce the expression of well-known AR-regulated genes (KLK3, TMPRSS2 and 
FKBP5) in two androgen dependent prostate cancer cell lines, LNCaP and VCaP. 
11KT and 11KDHT were also able to induce cell growth in both cell lines. Finally, 
proteomic analysis of VCaP cells revealed that that both 11KT and 11KDHT 
modulated the expression of known AR-regulated proteins. Collectively, this data 
confirmed that 11KT and 11KDHT are bone fide androgens and that their 
contribution to the development and progression of CRPC warrants further 
investigation (Pretorius et al., 2016). 
While it is clear that the intratumoral concentration of androgens is dependent on the 
conversion of inactive adrenal precursors to active androgens, the subsequent 
inactivation of androgens is equally as important.  Androgens are inactivated by 
either the 3αHSD catalysed reduction of 5α-reduced steroids and/or by uridine 5'-
diphospho-glucuronosyltransferase (UGT) catalysed glucuronidation (Bélanger et al., 
2003). We therefore measured the metabolism of both 11KT and 11KDHT in LNCaP 
and VCaP cells. Interestingly, we found that while T and DHT were rapidly 
inactivated by both cell lines, the metabolism of 11KT and 11KDHT occurred at a 
significantly lower rate. This observation suggests that 11KT and 11KDHT have the 
potential to remain active longer than T and DHT, further implicating these 11-
oxygenated steroids as a putative driving force behind the development and 
progression of CRPC (Pretorius et al., 2016). 
5. Congenital adrenal hyperplasia 
Congenital adrenal hyperplasia (CAH) is a collection of inherited conditions 
characterized by deficiencies in cortisol biosynthesis. The ensuing loss of negative 
feedback by cortisol on the hypothalamus and pituitary gland results in the excessive 
secretion of corticotropin releasing hormone (CRH) and ACTH, which in turn leads to 
hyperplasia of the adrenal cortex. This autosomal recessive condition is caused by 
mutations in genes encoding enzymes mediating adrenal steroidogenesis. The 
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deficiencies can be complete or partial, leading to a wide array of clinical 
presentations (Turcu and Auchus, 2015; White and Speiser, 2000). 
The most prominent cause of CAH is 21OHD, which is considered one of the most 
common autosomal recessive diseases, and accounts for over 90% of all CAH cases 
(Speiser and White, 2003). The loss of CYP21A2 function results in the 
accumulation of cortisol precursors which are subsequently diverted toward 
androgenic pathways (Fig. 3). Significant features associated with the androgen 
excess observed in 21OHD include in utero virilisation in females as well as 
epiphyseal maturation, premature pubarche, subfertility and rapid somatic growth in 
both sexes (Cabrera et al., 2016; Claahsen-van der Griten et al., 2008; Reisch et al., 
2009; Speiser and White, 2003; Stikkelbroeck et al., 2003).  
Treatment of 21OHD includes the administration of glucocorticoids and 
mineralocorticoids in order to re-establish the negative feedback on ACTH secretion 
(White and Speiser 2000). However, treatments often fail to blunt the early morning 
rise of ACTH, leading to physicians resorting to non-physiologic doses of 
glucocorticoids, which results in side effects such as bone loss, obesity and features 
of metabolic syndrome (Arlt et al. 2010; Finkielstain et al. 2012). Monitoring and 
optimizing clinical treatment therefore remains a challenge (Auchus and Arlt, 2013; 
Han et al., 2014). 
The significant accumulation of 17OH-PROG, a substrate of CYP21A2, which is a 
hallmark of 21OHD is used both for diagnostic purposes and to monitor the success 
of treatment (Kamrath et al. 2012). The accumulation of 17OH-PROG is due to both 
the loss of CYP21A2 function and the inability of human CYP17A1 to efficiently 
catalyse the conversion of 17OH-PROG to A4 (Fig. 3). Even though the Δ5 steroid 
17OH-PREG is the preferred substrate for the 17,20-lyase activity of human 
CYP17A1, the excessive  accumulation of 17OH-PROG can overcome this substrate 
presence and in so doing contribute to the excess production of androgens observed 
in 21OHD (Auchus et al., 1998; Turcu and Auchus, 2015). The resulting adrenal 
androgen precursors are further converted to T and DHT, both in the adrenal and in 
the peripheral tissue. To a lesser extent, estrogens such as estradiol and estrone are 
also produced in peripheral tissues (White and Speiser, 2000). 
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The so called “backdoor pathway” is an additional pathway for DHT biosynthesis, 
where adrenal 17OH-PROG can be converted to DHT without DHEA, 
androstenedione or testosterone as intermediates and appears to play an important 
role during male sexual differentiation (Arlt et al., 2004; Auchus, 2004; Flück et al., 
2011; Wilson et al., 2003). Accumulation of 17OH-PROG, as in patients with 21OHD, 
could reopen the backdoor pathway, with some evidence from urinary steroid 
profiling that this actually takes place in patients with CAH due to 21-hydroxylase 
deficiency (Kamrath et al., 2012). In this pathway 17OH-PROG is not metabolised by 
cytochrome P450 steroid 21-hydroxylase (CYP21A2), but is instead reduced by 
SRD5A1, yielding 17OH-dihydroprogesterone (Wilson et al., 2003). 17OH-
dihydroprogesterone is subsequently metabolised by 3α-hydroxysteroid 
dehydrogenase activity to form 5α-pregnane-3α,17α-diol-20-one (pdiol), which is a 
substrate for the 17,20-lyase activity of CYP17A1. The resulting androsterone (AST) 
is reduced by AKR1C3 to form 3α-adiol. Finally, 3β-epimerase activity converts 3α-
adiol to DHT (Auchus, 2004).   
The blockage caused by CYP21A2 deficiency has also been shown to result in the 
accumulation of additional steroids, including 16α-hydroxyprogesterone, 11β-
hydroxyprogesterone and 21-deoxycortisol (Turcu et al., 2015). Recently, Turcu and 
colleagues showed that the levels of four 11-oxygenated C19 steroids, 11OHA4, 
11KA4, 11OHT and 11KT, are significantly (3- to 4-fold) elevated in both male and 
female patients with classic 21OHD when compared to age-matched controls (Table 
2). The authors suggest that since 11KT is an active androgen, this steroid may be 
clinically relevant to the hyperandrogenism associated with 21OHD. Significantly, it 
was shown that 11KT tended to correlate inversely with T in males with 21OHD, 
strongly suggesting that 11KT was able to suppress gonadotropins and T production 
from the testes in men (Turcu et al., 2016). This finding supports the idea that 11KT 
is capable of eliciting physiological effects. Furthermore, the authors suggest that the 
ratio of T to 11KT might be  ideal for monitoring the treatment of men with 21OHD 
(Turcu et al., 2016). Indeed, as the 11-oxygenated steroids are primarily derived 
from the adrenal, they may be superior biomarkers of adrenal androgen 
hyperandrogenism in 21OHD than other C19 steroids which have multiple origins. 
For example, A4 and T are produced by both the adrenals and the gonads which 
may explain why there is no good correlation between these steroids and the clinical 
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evidence of androgen excess in 21OHD patients (Krone et al., 2000; Speiser et al., 
1992; Turcu et al., 2016). 
The prominent adrenal C19 steroids DHEA and DHEAS, on the other hand, are also 
not good markers of hyperandrogenism in classic 21OHD as they are 
disproportionally suppressed by glucocorticoid treatment (Finkielstain et al., 2012; 
Kamrath et al., 2012; Turcu et al., 2016). The finding that 11-oxygenated steroids are 
elevated in 21OHD therefore not only holds promise for better understanding the 
effects of androgen excess associated with 21OHD, but also as biomarkers for 
disease severity and treatment response in both male and female patients.  
6. Polycystic Ovary Syndrome 
 
Polycystic ovarian syndrome (PCOS) is a common grouping of conditions, which 
affects 4-10% of women of reproductive age (Azziz et al., 2004; Knochenhauer et al., 
1998) and is characterized by biochemical and/or clinical evidence of androgen 
excess and chronic anovulation, with or without polycystic appearance of the ovaries 
on ultrasound, the latter reflecting enhanced folliculogenesis with premature 
developmental arrest. Importantly, women with PCOS have an increased adverse 
metabolic risk, with a higher prevalence of insulin resistance, type 2 diabetes, arterial 
hypertension and surrogate parameters of cardiovascular risk (Azziz et al., 2004; 
Legro, 2003; Ovalle and Azziz, 2002; Wild, 2002). 
 
The most common clinical feature of PCOS is hyperandrogenism. Biochemical 
evidence of androgen excess is commonly found in PCOS patients and, in turn, can 
negatively affect menstrual cycle and ovarian function (Azziz et al., 2004). The origin 
of excess androgen production in PCOS patients is, however, controversial. Several 
studies indicate that the ovary exhibits abnormally high T production in the majority 
of PCOS cases (Stahl and Greenblatt, 1973; Stahl et al., 1973). Stimulation of 
ovarian androgen production with GnRH agonists elicits higher responses in PCOS 
patients (Barnes et al., 1989; Ehrmann et al., 1992) and the level of circulating 
androgens are higher in PCOS patients than in healthy woman even after adrenal 
suppression by dexamethasone (Lachelin et al., 1982), suggesting an ovarian origin. 
Still other studies indicate that adrenal androgens contribute to the androgen excess 
in PCOS. Androgen levels remain higher in PCOS patients than in healthy women 
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even after ovarian suppression with GnRH agonists (Cedars et al., 1992; Chang et 
al., 1983; Rittmaster and Thompson, 1990).Conversely, there is also ample evidence 
for an enhanced adrenal contribution to androgen excess in PCOS. An exaggerated 
androgen response is observed in PCOS patients after ATCH stimulation 
(Anapliotou et al., 1990; Azziz et al., 1998; Turner et al., 1992). Moreover, using 
adrenal vein sampling, it was shown that the increased T seen in PCOS patients 
could originate from the adrenal as well as from the ovary (Parker et al., 1975; Stahl 
and Greenblatt, 1973; Stahl et al., 1973). In addition, approximately 50% of women 
with PCOS were previously shown to have elevated serum levels of DHEAS and 
11OHA4, two androgens that are almost exclusively secreted by adrenal glands 
(Carmina et al., 1986; Stanczyk et al., 1991). Interestingly, brothers of PCOS 
patients have also been shown to have elevated serum DHEAS (Legro et al., 2002). 
Recent work has shown that patients with impaired DHEA sulfation due to 
inactivating mutations in the sulfate donor-generating enzyme PAPSS2 show not 
only significant androgen excess, resulting from enhanced conversion of DHEA to 
active androgens, but also an overt PCOS phenotype (Noordam et al., 2009; 
Oostdijk et al., 2015). 
Taken together, evidence therefore suggests that both the ovaries and adrenal 
contribute to the hyperandrogenism observed in PCOS. However, other studies have 
highlighted an additional role of the peripheral tissue in androgen activation. For 
example, increased peripheral conversion of T to DHT has been observed due to up-
regulated 5α-reductase activity (Fassnacht et al., 2003; Stewart et al., 1990).  
 
Even though PCOS can be considered a collection of endocrine disorders which 
share the common characteristic of hyperandrogenism, serum T alone remains the 
most commonly measured and widely available marker for the estimation of 
biochemical androgen excess in PCOS (Azziz et al., 2004). Quantification of multiple 
androgens, rather than just T may therefore significantly expand our ability to 
distinguish different forms of PCOS (O’Reilly et al., 2014). Serum A4 is inconsistently 
measured in PCOS patients as clinicians remain uncertain about its diagnostic value. 
Limited previous work suggests that 10% of PCOS patients may be misclassified as 
normo-androgenemic if A4 is not measured (Knochenhauer et al., 1998). 
Measurement of T alone may therefore not be sufficient to categorize patients as 
normoandrogenemic or hyperandrogenemic. A recent study in a large cohort of 
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PCOS patients has shown that increased A4 is a more sensitive marker of PCOS-
related androgen excess and that the type and severity of androgen excess 
determines the extent of metabolic risk in PCOS (O’Reilly et al., 2014). This finding 
has been recognized as field changing (Conway et al., 2014; Keevil, 2014) and was 
recently confirmed by another large study (Pasquali et al., 2016). 
 
Previous studies have considered the 11-oxygenated adrenal steroid, 11OHA4, as a 
potential marker for adrenal androgen production in PCOS, though results were 
inconclusive (Carmina, 1992; Holownia et al., 1992; Hudson et al., 1990; Owen et 
al., 1992; Stanczyk et al., 1991). For example, studies have shown that 11OHA4 
levels are more sensitive to adrenal stimulation and suppression than DHEAS 
(Stanczyk et al., 1991) and that the ratio of A4 to 11OHA4 may be a good marker for 
adrenal hyperandrogenism (Carmina, 1992), while others have found that although 
11OHA4 is elevated in the majority of PCOS woman, it is not a reliable marker for 
this condition (Owen et al., 1992). It is, however, worth noting that many of these 
studies relied on immuno-based assays, which are not accurate and have been 
surpassed by the use of modern mass spectrometry based assays (Bloem et al., 
2015). 
 
To date, and to the best of our knowledge, other 11-oxygenated steroids have never 
been considered in the context of PCOS. Given that 11OHA4 is clearly elevated in 
PCOS (Carmina, 1992; Carmina et al., 1986; Stanczyk et al., 1991), and that 
11OHA4 is a precursor to active 11-oxygenated androgens (K.-H. Storbeck et al., 
2013), the peripheral metabolism of 11OHA4 and other adrenal 11-oxygenated 
steroids may contribute to the symptoms associated with androgen excess. Since 
11KDHT has been found to be as potent as DHT (Pretorius et al., 2016) and 
peripheral 5α-reductase activity is increased in PCOS patients (Stewart et al., 1990), 
the reduction of 11KT to 11KDHT may be significant.  
 
Furthermore, 11-oxygenated steroids could potentially serve as biomarkers of 
PCOS. Indeed, recent advances in analytical techniques now make it possible to 
simultaneously and accurately measure multiple steroids in a single sample, thereby 
significantly expanding current diagnostic capabilities (Bloem et al., 2015). Including 
a panel of C19 steroids such as T, A4, DHEA, DHEAS, DHT, 11OHA4, 11KA4, 
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11OHT, 11KT and 11KDHT could therefore potentially improve diagnostics of PCOS 
and may result in clearer differentiation of subtypes in this common endocrine 
disorder. 
7. Conclusion 
The identification of 11-oxygenated steroids with androgenic activity, especially the 
recent characterisation of 11KT and 11KDHT, challenges the paradigm that T and 
DHT are the only potent natural androgens and thus have significant implications for 
our understanding of androgen related diseases. Furthermore, recent advances in 
technology allowing for the accurate quantification of physiologically relevant 
concentrations of these steroids may be useful for diagnostic and prognostic 
purposes. Panels of canonical C19 steroids and the 11-oxygenated steroids may 
allow for better improved diagnosis and classification of androgen related diseases. 
Taken together, 11OHA4 and its 11-oxygenated metabolites, should no longer be 
ignored when considering androgen related diseases. 
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Table 1. Concentrations of C19 steroids in adrenal vein samples (AVS) and serum from 
healthy controls and 21OHD patients. 
Steroid AVS1 
(nmol/L) 
Controls2 
(nmol/L) 
21OHD2 
(nmol/L) 
DHEAS  3827 ± 1317 3793.4  (1585.1-5066.5) 508.7 (213.0-1745.2) 
DHEA 125 ± 56.9 6.0 (4.1-11.0) 1.0 (0.55-2.9) 
A4  79.0 ± 46.9 1.5 (0.77-2.2) 5.4 (2.5-13.6) 
T 0.78 ± 0.26 0.90 (0.42-10.7) 2.8 (1.3-5.6) 
11OHA4 157 ± 96.2 3.9 (2.3-5.1) 11.6 (6.2-26.2) 
11KA4 0.99 ± 0.33 1.0 (0.67-1.4) 3.2 (1.9-4.8) 
11OHT 0.48 ± 0.17 0.49 (0.30-0.69) 1.9 (0.69-3.4) 
11KT 0.39 ± 0.09 1.7 (0.96-2.6) 5.7 (3.5-12.1) 
1Data from Rege et al 2013. Expressed as mean ± SEM (n=7) 
2Data from Turcu et al 2016. Expressed as median (interquartile range) (n=38 for both controls and 
21OHD) 
 
Table 2. Androgenicity of C19 steroids 
Steroid % induction  
at 1nM1 
Potency2 
(nM) 
Potency3 
(nM) 
Efficacy3 
(%) 
A4 NM 87 - - 
T 60.9 0.52 19.6 96.21 
DHT 100 - 3.00 99.14 
11OHA4 2.3 * - - 
11KA4 3.4 469 - - 
11OHT 30.0 2.3 - - 
11KT 62.1 2.7 15.8 107.59 
11KDHT 96.2 - 1.35 113.84 
1Data from Storbeck et al. 2013. All values relative to that of DHT which was set at 100% 
2Data from Rege et al. 2013. Induction was relative to that of a basal control. 
3Data from Pretorius et al. 2016. Efficacies relative to that of the synthetic AR agonist mibolerone 
which was set at 100%.  
* No measurable response   
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Fig 1. C19 steroid biosynthesis in the adrenal. The biosynthesis of 11-oxygenated 
steroids are shown in the grey box. 3βHSD2, 3β-hydroxysteroid dehydrogenase type 
2; 11KA4, 11-ketoandrostenedione; 11KT, 11-ketotestosterone; 11OHA4, 11β-
hydroxyandrostenedione; 11OHT, 11β-hydroxytestosterone; 17OH-PREG, 17α-
hydroxypregnenolone; 17OH-PROG, 17α-hydroxyprogesterone; A4, 
androstenedione; AKR1C3, aldo-keto reductase 1C3; CYB5A, cytochrome b5; 
CYP11A1, cytochrome P450 cholesterol side chain cleavage; CYP11B1, cytochrome 
P450 11β-hydroxylase; CYP17A1, cytochrome P450 17α-hydroxylase/17,-20-lyase; 
DHEA, dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate; DHT, 
5α-dihydrotestosterone; PREG, pregnenolone; SRD5A1, steroid 5α-reductase type 
1; StAR, steroidogenic acute regulatory protein; T, testosterone. 
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Fig 2. C19 steroid metabolism in castration resistant prostate cancer. 3α-adiol, 3α-
androstanediol 3βHSD1, 3β-hydroxysteroid dehydrogenase type 1; 5α-dione, 5α-
androstanedione; 11βHSD2, 11β-hydroxysteroid dehydrogenase type 2; 11K-3α-
adiol, 11-keto-3α-androstanediol; 11K-5α-dione, 11-keto-5α-androstanedione; 
11KA4, 11-ketoandrostenedione; 11KAST, 11-ketoandrosterone; 11KDHT, 11-keto-
5α-dihydrotestosterone; 11KT, 11-ketotestosterone; 11OH-5α-dione, 11β-hydroxy-
5α-androstanedione; 11OHA4, 11β-hydroxyandrostenedione; 11OHAST, 11β-
hydroxyandrosterone; 11OHT, 11β-hydroxytestosterone; 17βHSD2, 17β-
hydroxysteroid dehydrogenase type 2; 17βHSD6, 17β-hydroxysteroid 
dehydrogenase type 6; 17OH-PREG, 17α-hydroxypregnenolone; 17OH-PROG, 17α-
hydroxyprogesterone; A4, androstenedione; AKR1C2, aldo-keto reductase 
1C2AKR1C3, aldo-keto reductase 1C3; AST, androsterone; DHEA, 
dehydroepiandrosterone; DHT, 5α-dihydrotestosterone; SRD5A1, steroid 5α-
reductase type 1; T, testosterone. 
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Fig 3. C19 steroid metabolism during 21-hydroxylase deficiency. The biosynthesis of 
11-oxygenated steroids are shown in the grey box. The ‘backdoor pathway is shown 
in dark grey.  3α-adiol, 3α-androstanediol; 3βHSD2, 3β-hydroxysteroid 
dehydrogenase type; 11KA4, 11-ketoandrostenedione; 11KT, 11-ketotestosterone; 
11OHA4, 11β-hydroxyandrostenedione; 11OHT, 11β-hydroxytestosterone; 
17βHSD6, 17β-hydroxysteroid dehydrogenase type 6; 17OH-PREG, 17α-
hydroxypregnenolone; 17OH-PROG, 17α-hydroxyprogesterone; A4, 
androstenedione; AKR1C, aldo-keto reductase 1C; AKR1C3, aldo-keto reductase 
1C3; AST, androsterone; CYB5A, cytochrome b5; CYP11A1, cytochrome P450 
cholesterol side chain cleavage; CYP11B1, cytochrome P450 11β-hydroxylase; 
CYP17A1, cytochrome P450 17α-hydroxylase/17,-20-lyase; DHEA, 
dehydroepiandrosterone; DHEAS, dehydroepiandrosterone sulphate; DHT, 5α-
dihydrotestosterone; Pdione, 5α-pregnane-17-ol-3,20-dione; Pdiol, 5α-pregnane-
3α,17α-diol-20-one; PREG, pregnenolone; PROG, progesterone; SRD5A1, steroid 
5α-reductase type 1; StAR, steroidogenic acute regulatory protein; T, testosterone. 
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